Interleukin-2 and cancer: Critical analysis of results, problems and expectations

Medical Hypotheses

Volumn 60, Issue 2, 2003, Pages 202-208

  Alileche, Abdelkrim ^a,b  

^a Immunol and Microbiology Department ^*  (Tunisia)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ANEMIA; ANGINA PECTORIS; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER REGRESSION; CELL GROWTH; CHILL; COMA; DEATH; DIARRHEA; DISORIENTATION; DRUG MEGADOSE; ENDOTHELIUM CELL; FIBROBLAST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; IMMUNOCOMPETENT CELL; INFECTION; MALAISE; MOUSE; NAUSEA; NONHUMAN; OLIGURIA; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VASCULAR DISEASE;

EID: 0037320981     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00359-6     Document Type: Article

References (96)

1. Burnet M. F. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
2. Cornelis J. M., Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75: 235-282.
3. Hiesse C., Charpentier B. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25 year period. Transplant Proc 1997; 71: 517-520.
4. Gao S. J., Moore P. S. KSHV antibodies among Americans, Italians and Ugendants with and without Kaposis's sarcoma. Nature 1996; 2: 925-929.
5. Stone O. J. Acute local inflammation causing generalized increased ground substance viscosity: guttate psoriasis, Reiter's syndrome, adjuvant disease, cancer regression. Med Hypotheses 1988; 25: 141-145.
6. Lunardi-Iskandar Y., Gallo R. C. Tumorigenesis and metastasis of neoplastic Kaposis's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995; 375: 64-68.
7. Coley W. B. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus Prodigious with a report of 160 cases. Bull John Hopkins Hosp 1896; 7: 157.
8. Mathe G., Schwarzenberg L. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1: 697-699.
9. Schwarzenberg L., Schneider M. Attempts adoptive immunotherapy of acute leukemia by leukocyte transfusions. Lancet 1966; 2: 365-368.
10. Ratliff T. L. Role of the immune response in BCG bladder cancer. Eur Urol 1992; 21(Suppl. 21): 17-21.
11. Waldmann T. A. Therapy of patients with human T cell lymphotropic virus I induced T cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin 2. Blood 1986; 72: 1805-1816.
12. Pastan I., Fitzgerald D. J. P. Immunotoxins. Cell 1986; 47: 641.
13. Sogn J. A. Tumor immunology: the glass is half full. Immunity 1998; 9: 757-763.
14. Morgan D. A., Gallo R. C. Selective in vitro growth of T lymphocytes from normal bone marrow. Science 1976; 193: 1007-1008.
15. Taniguchi T., Fujita T. Structure and expression of a cloned cDNA for human interleukin 2. Nature 1983; 302: 305-307.
16. Nelson B. H., Willerford D. M. Biology of the interleukin 2 receptor. Adv Immunol 1998; 70: 1-81.
17. Lenardo M. Interleukin 2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991; 353: 858-861.
18. Rafaeli Y., Abbas A. K. Biochemical mechanisms of IL-2 regulated Fas mediated T cell apoptosis. Immunity 1998; 8: 615-623.
19. Grimm E. A., Rosenberg S. A. The lymphokine activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
20. Rayner A. A., Lotze M. T. Lymphokine activated killer (LAK) cells, analysis of effectors relevant to the immunotherapy of human cancer. Cancer 1985; 55: 1327-1333.
21. Ortaldo J. R., Overton R. Lymphokine activated killer cells: analysis of progenitors and effectors. J Exp Med 1986; 164: 1193-1205.
22. Muul L. M., Director E. P. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989-995.
23. Itoh K., Balchs C. M. Interleukin 2 activation of cytolytic T lymphocytes infiltrating into human metastatic melanoma. Cancer Res 1986; 46: 3011-3017.
24. Donoline J. H., Rosenberg S. A. The fate of interleukin 2 after in vivo administration. J Immunol 1983; 130: 2203-2208.
25. Chang A. E., Rosenberg S. A. Systemic administration of recombinant IL-2 in mice. J Biol Response Mod 1984; 3: 561-6572.
26. Rosenberg, Schwarz S. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin 2. J Exp Med 1985; 161: 1169-1188.
27. Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngenic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159: 495-507.
28. Bubenick J., Toulcova A. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparation. Folia Biol (Praha) 1986; 32: 384-391.
29. Vaage J. Local and systemic effects during interleukin 2 therapy of mouse mammary tumors. Cancer Res 1987; 47: 4296-4298.
30. Barbery H., Schwulera U. Inhibition of tumor growth in a mouse fibrosarcoma after interleukin 2 application. Immunobiology 1986; 172: 383-390.
31. Van Der Broek M., Hengartner H. Decreased tumor surveillance in perforin deficient mice. J Exp Med 1996; 184: 1781-1790.
32. Kagi D., Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin deficient mice. Nature 1994; 369: 31-37.
33. Smyth M. J., Trapain J. A. Perforin mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-760.
34. Smyth M. J., Scalzo A. A. Perforin is major contributor to NK cell control of tumor metastasis. J Immunol 1999; 162: 6658-6662.
35. Rosenberg S. A., White D. E. A progress report on the treatment of 157 patients with advanced cancer using activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Eng J Med 1987; 316: 889-897.
36. Fischer R. I., Paietta E. Metastatic renal cell carcinoma treated with IL-2 and lymphokine activated killer cells. A phase I trial. Ann Inter Med 1988; 108: 518-523.
37. Philip T., Clavel M. Interleukin 2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first year experience on 20 patients. Cancer Treat Rev 1989; 16(Suppl. A): 91-104.
38. Parmiani G., Carrabla M. Cytokines in cancer therapy. Immunol Lett 2000; 74: 41-42.
39. Chouaib S., Blay J. Y. The host tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997.
40. West W. H., Oldhan R. K. Constant infusion recombinant interleukin 2 in adoptive immunotherapy and advanced cancer. N Eng J Med 1987; 316: 898-905.
41. Kaplan G., Smith K. A. Rational immunotherapy with interleukin 2. Biotechnology 1992; 10: 157-162.
42. Cortesina G., Forni G. Treatment of recurrent squamous cell carcinoma of head and neck with low dose of interleukin 2 (IL-2) injected perilymphatically. Cancer (Phila) 1988; 62: 2482-2485.
43. Goey S. H., Stoter G. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995; 72: 1283-1288.
44. Kaplan G., Cohn Z. A. The reconstitution of cell mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 1989; 169: 893-907.
45. Khatri V. P. Ultra low dose interleukin 2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS associated malignancies. J Clin Invest 1998; 101: 1373-1378.
46. Pahwa R., Good R. A. Recombinant interleukin 2 therapy in severe combined immunodeficiency diseases. Proc Natl Acad Sci USA 1989; 86: 5069-5073.
47. Fearon E. R., Frost P. Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
48. Colombo M. P., Forni G. Immunotherapy I: cytokine gene transfer strategies. Cancer Metastais Rev 1997; 16: 421-432.
49. Plaisance S., Azzarone B. Expression of the interleukin 2 receptor on human fibroblasts and its biological significance. Int Immunol 1992; 4: 739-746.
50. Plaisance S., Azzarone B. The IL-2 receptor present on human embryonic fibroblasts is functional in the absence of p64/IL-2Rγ. Int Immunol 1993; 5: 843-848.
51. Hicks C., Penny R. Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors 1991; 5: 201-208.
52. Frasier S. K., Wu K. Influence of natural and recombinant IL-2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of Prostaglandin H synthase. J Clin Invest 1988; 82: 1877-1883.
53. Benveniste E. N., Merrill J. E. Stimulation of oligodendroglial cell proliferation and maturation by IL-2. Nature 1986; 321: 610-613.
54. Yodoi J., Uchiyama T. Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol Today 1992; 13: 405-411.
55. Rimoldi D., Carrel S. Expression of IL-2 receptor in human melanoma cells. Anticancer Res 1993; 13: 555-564.
56. Plaisance S., Azzarone B. Human melanoma cells express a functional interleukin 2 receptor. Int J Cancer 1993; 55: 164-170.
57. Birch M., Hart I. R. Isolation and characterization of human melanoma cell variants expressing high and low level of CD 44. Cancer Res 1991; 51: 6660-6667.
58. Alileche A., Azzarone B. Human melanoma cell line M14 secretes a functional interleukin 2. Oncogene 1993; 8: 1791-1796.
59. Doucet C., Azzarone B. Role of interleuktn 2 and IL-15 in the tumor progression of a melanoma cell line MELP derived from an IL-2 progressor patient. Melanoma Res 1997; 7(Suppl. 2): S7-S17.
60. Polamares T., Guillem E. B. The addition on interleukin 2 and cyclophosphamide therapy can facilitate tumor growth of B16 melanoma. Cancer Immunol Immunolther 1995; 40: 292-298.
61. Weidman E., Whiteside T. L. Receptors on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992; 52: 5963-5970.
62. Sacchi M., Whiteside T. L. Local adoptive immunotherapy of human head and neck cancer xenograffs in nude mice with lymphokine activated killer cells and interleukin 2. Cancer Res 1990; 50: 3113-3118.
63. Sacchi M., Whiteside T. L. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int J Cancer 1991; 47: 784-791.
64. Reichert T. E., Whiteside T. L. Interleukin 2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000; 19: 514-525.
65. Porta C., Mutti L. Interleukin 2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. J Cell Physiol 2000; 185: 126-134.
66. Astoul P., Boutin C. Intrapleural administration of interleukin 2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 1998; 83: 2099-2104.
67. Lissoni P., Tancini G. Intracavitary administration of interleukin 2 as aplliative therapy for neoplastic effusions. Tumori 1992; 78: 118-120.
68. Yasumura S., Whiteside T. L. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor inhibition by interleukin 2. Int J Cancer 1994; 59: 225-234.
69. Paciotti G. F., Tamarkin L. Interleukin 2 differntially affects the proliferation of a hormone dependent and a hormone independent human breast cancer cell line in vitro and in vivo. Anticancer Res 1988; 8: 1233-1239.
70. Royula M., Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000; 18: 135-146.
71. Ochsenbein A. F., Zinkernagel R. M. Immune surveillance against a solid tumor fails because of immunological surveillance. Proc Natl Acad Sci USA 1999; 96: 2233-2238.
72. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
73. Pekarek L. A., Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 1995; 181: 435-440.
74. Dimitriadou V., Koutsilieris M. Mast cell tumor cell interaction: for or against tumor growth and metastasis. Anticancer Res 1997; 17: 1541-1550.
75. Dong Z., Fidler I. J. Macrophage derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801-810.
76. Umansky V., Rocha M. New insights into tumor host interaction in lymphocyte metastasis. J Mol Med 1996; 74: 353-363.
77. Igney F. H., Krammer P. H. Tumor counterattack, concept and reality. Eur J Immunol 2000; 30: 725-731.
78. Porta C., De Amici M. Eosinophils and serum eosinophils cationic proteins in interleukin 2 based immunotherapy of cancer. Br J Heamatol 1998; 100: 607-608.
79. Laures M. A. Effect of shistosoma mansoni and cyclophosphamide on a mouse fibrosarcoma. Braz J Med Biol Res 1988; 21: 93-96.
80. Dvorak H. F. Tumors: wounds that do not heal. N Eng J Med 1986; 315: 1650-1659.
81. Van Den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res 1988; 50: 159-196.
82. Liotta L. A. Tumor invasion and metastasis: role of basement membrane. Am J Pathol 1984; 117: 339-384.
83. Singh S., Screiber H. Stroma is critical for preventing or permitting immunological destruction of antigen cancer cells. J Exp Med 1992; 175: 139-146.
84. Camps J. L., Chung L. W. K. Fibroblast mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 1990; 87: 75-79.
85. Gregoire M., Lieubeau B. The role of fibroblasts in tumor behavior. Cancer Metastasis Rev 1995; 14: 339-350.
86. Picard O., Poupon M. F. Fibroblast dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res 1986; 46: 3290-3294.
87. Fukumura D., Seed B. Tumor induction of VGEF promoter activity in stromal cells. Cell 1998; 94: 715-725.
88. Folkman J. Antiangiogenesis: new concepts for therapy of solid tumors. Ann Surg 1972; 175: 409-416.
89. Cornil I., Kerbel R. S. Fibroblast cell interaction with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 1991; 88: 6028-6032.
90. Lu C., Kerbel R. S. Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulation during human melanoma progression. J Cell Biol 1993; 120: 1281-1288.
91. Blay J. Y., Philip T. Serum level of interleukin 6 as a prognosis in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.
92. Martin M. S., Martin F. An immunohistological study of cells infiltrating progressive and regressive tumors induced bu two variants subpopulation of a rat colon cancer cell line. Int J Cancer 1987; 40: 87-93.
93. Lieubeau B., Gregoire M. The role of transforming growth factor β1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 1994; 54: 6526-6532.
94. Laird D., Cherrington J. M. SU 6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-4160.
95. Fong T. A., McMahon G. SU 5416 is a potent and selective inhibitor of the vascular endothelial growth factor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
96. Straw L. M., Shawer L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-3545.